Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Operating Leases (2022 - 2025)

Zentalis Pharmaceuticals has reported Operating Leases over the past 4 years, most recently at $35.7 million for Q4 2025.

  • Quarterly results put Operating Leases at $35.7 million for Q4 2025, down 9.79% from a year ago — trailing twelve months through Dec 2025 was $35.7 million (down 9.79% YoY), and the annual figure for FY2025 was $35.7 million, down 9.79%.
  • Operating Leases for Q4 2025 was $35.7 million at Zentalis Pharmaceuticals, down from $36.7 million in the prior quarter.
  • Over the last five years, Operating Leases for ZNTL hit a ceiling of $47.0 million in Q1 2023 and a floor of $35.7 million in Q4 2025.
  • Median Operating Leases over the past 4 years was $43.3 million (2023), compared with a mean of $42.1 million.
  • Biggest five-year swings in Operating Leases: changed 0.0% in 2024 and later fell 15.16% in 2025.
  • Zentalis Pharmaceuticals' Operating Leases stood at $45.2 million in 2022, then dropped by 4.46% to $43.2 million in 2023, then fell by 8.28% to $39.6 million in 2024, then dropped by 9.79% to $35.7 million in 2025.
  • The last three reported values for Operating Leases were $35.7 million (Q4 2025), $36.7 million (Q3 2025), and $37.7 million (Q2 2025) per Business Quant data.